New Drug Approvals
Follow New Drug Approvals on WordPress.com

FLAGS AND HITS

Flag Counter
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO

Archives

Categories

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Researchgate

Anthony Melvin Crasto Dr.

  Join me on Facebook FACEBOOK   ...................................................................Join me on twitter Follow amcrasto on Twitter     ..................................................................Join me on google plus Googleplus

MYSELF

DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 36Yrs Exp. in the feld of Organic Chemistry,Working for AFRICURE PHARMA as ADVISOR earlier with GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, NO ADVERTISEMENTS , ACADEMIC , NON COMMERCIAL SITE, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution, ........amcrasto@gmail.com..........+91 9323115463, Skype amcrasto64 View Anthony Melvin Crasto Ph.D's profile on LinkedIn Anthony Melvin Crasto Dr.

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Recent Posts

Ayurveda……..Saffron, केसरी కుంకుమ పువ్వు زعفران 사프란


Saffron – valuable stigmas, or threads, are painstakingly plucked, piled, and dried. flower

Saffron (pronounced /ˈsæfrən/ or /ˈsæfrɒn/)[1] is a spice derived from the flower of Crocus sativus, commonly known as the saffron crocus. Crocus is a genus in the family Iridaceae. Saffron crocus grows to 20–30 cm (8–12 in) and bears up to four flowers, each with three vivid crimson stigmas, which are the distal end of a carpel.[2] The styles and stigmas are collected and dried to be used as a seasoning and colouring agent in cooking. Saffron, long among the world’s most costly spices by weight,[3][4][5] is native to Greece orSouthwest Asia[6][4] and was first cultivated in Greece.[7] As a genetically monomorphic clone,[8] it was slowly propagated throughout much of Eurasia and was later brought to parts of North Africa, North America, and Oceania. The saffron crocus, unknown in the wild, probably descends from Crocus cartwrightianus, which originated in Crete;[8] C. thomasii and C. pallasii are other possible precursors.[9][10] The saffron crocus is a triploid that is “self-incompatible” and male sterile; it undergoes aberrant meiosis and is hence incapable of independent sexual reproduction—all propagation is by vegetative multiplication via manual “divide-and-set” of a starter clone or by interspecific hybridisation.[11][10] If C. sativus is a mutant form of C. cartwrightianus, then it may have emerged via plant breeding, which would have selected for elongated stigmas, in late Bronze Age Crete.[12] Saffron’s taste and iodoform– or hay-like fragrance result from the chemicals picrocrocin and safranal.[13][14] It also contains a carotenoid pigment, crocin, which imparts a richgolden-yellow hue to dishes and textiles. Its recorded history is attested in a 7th-century BC Assyrian botanical treatise compiled under Ashurbanipal,[15] and it has been traded and used for over four millennia. Iran now accounts for approximately 90% of the world production of saffron.[16] Saffron is obtained from dried style and stigma of reddish-orange flowers of a plant. Kesar or Saffron is the most expensive spice of world as stigmas of about 60, 000 hand collected flowers provide only half- kilograms of it. Saffron is used as coloring and flavoring ingredient in the preparation of various dishes. It is also used as traditional medicine for many diseases and in cosmetics. Saffron has a distinct aromatic odour and a bitter, pungent taste. Medicinally it is stimulant (stimulates levels of physiological or nervous activity), aphrodisiac, improves digestion and appetite. It increases blood flow in pelvic region on oral intake. Its over-doses is a narcotic poison. Saffron is always used in small doses. It is a popular remedy for promoting menstruation.

 saffron_desibantu

Saffron is the most expensive herb harvested from the stigma of the Crocus sativus flower. It is dark orange and thread like in appearance, with a spicy flavor, nice yellow to orange color and pungent odor.

  •   The plant is grown in India, Spain, France, Italy, the Middle East, and the eastern Mediterranean region.
  • Over 200,000 crocus stigmas must be harvested to produce one pound of saffron.
  • Saffron is harvested by drying the orange stigma which are 3 of them in one Crocus sativus flower over fire.
  • This volume makes the herb extremely expensive and quite often adulterated.
  • Saffron is prescribed as a herbal remedy to stimulate the digestive system, ease colic and stomach discomfort, and minimize gas.
  • It is also used as an emmenagogue, to stimulate and promote menstrual flow in women.
  • Additional human studies have indicated that saffron has powerful antioxidant properties; that is, it helps to protect living tissues from free radicals and other harmful effects of oxidation.
  • Two chemical components of saffron extract, crocetin and crocin, reportedly improved memory and learning skills. These properties indicate that saffron extract may be a useful treatment for neurodegenerative disorders and related memory impairment.
  • In ancient India, robes were traditionally dyed a golden color from the crocin chemical dye that is found in saffron.
  • In fact, after Buddha had died, the Buddhist priests made this golden saffron color their official color of their robes.
  • Saffron was used by Greeks and Romans as a perfume on behalf of its pleasant aroma.
  • Cleopatra used to use saffron as a type of cosmetic. And now a days it is used in face creams as a fairness cream.
  • In the Middle Ages, one could be sentenced to the punishment of being buried alive if they tried to alter saffron by adding in other substances.
  • Romans used to take baths infused with saffron.
  • In order to cure hang-overs, Romans would sleep with expensive pillows that were stuffed with saffron.
  • Saffron is extensively used in Indian Cuisine and Middle Eastern Cuisine.

Scientific classification

  • Kingdom:Plantae
  • Division:Magnoliophyta
  • Class:Liliopsida
  • Order:Asparagales
  • Family:Iridaceae
  • Genus:Crocus
  • Species:C. sativus

Vernacular Names

SANSKRIT:Bhavarakta, Saurab, Mangalya, Kumkum ENGLISH:Saffron, Crocus PERSIAN:Zafrahn;Zipharana;GUJARATI:Keshar, Kesar KANNADA:Kunkuma, Kesari, MALAYALAM:Kunkuma Puvu MARATHI:Keshar PUNJABI:Kesar, Keshar TAMIL:Kungumapuvu TELUGU:Kunkuma Puvvu URDU:Zafran Parts Used:Dried stigmas and tops of the styles of Crocus sativus flowers. Habitat:Saffron is Cultivated in Kashmir, Kishtwar (Jammu) and in Nepal. Commercially, it is grown in Spain, France, Italy, Greece, Turkey, and China. Energetics:Pungent, bitter, Hot in potency

Plant description

Perennial tuber plant;Leaves radical,  linear,  dark green above,  pale green below,  enclosed in a membranous sheath;large Apurple or lilac colored flowers;Corolla in two segments, between which the long styles hang out;Stigmas three, large, nearly an inch long, rolled at the edges, bright orange bitter and warming taste.

Constituents of Saffron

Saffron contains three crystalline colouring matters ?-crocetin, ?-crocetin and ?-crocetin. It also contains essential oil a number of carotenoid pigments. The essential oil obtained from stigmas contains thirty-four or more components, viz. terpenes, terpene alcohols, and esters.

Medicinal Uses of Saffron

Saffron is used as condiment and colouring ingredient in several dishes. It is also used as a medicinal herb in fevers, enlargement of the liver, cough and asthma, anaemia, seminal debility rheumatism and neuralgia. Saffron is nervine tonic, sedative, antispasmodic expectorant, stomachic, diaphoretic and emmenagogue. In low doses Saffron stimulates gastric secretion and thus improves digestion. In large dose it increases flow of blood in pelvic region, stimulate uterine smooth muscles and can cause abortion.

  1. Saffron oral use gives relief in respiratory ailments. In cough and cold a pinch of Saffron is taken with a glass of milk.
  2. In painful urination and other urinary disorder the decoction of Saffron or infused tea should be taken.
  3. In irritation in eyes, crushed saffron should be mixed with honey and this should be applied in eyes.
  4. In looseness of bowels saffron is given children with ghee. It can also be given with half a teaspoon of lemon juice.
  5. For pneumonia in kids, few threads of saffron are added to 10-15 ml juice of bitter gourd leaves and given twice a day.
  6. Saffron is added to meals for regulating the menstrual cycle. It also gives relief in painful menstruation, PMS (premenstrual syndrome) and promotes fertility.
  7. For sexual weakness, about 250 mg of saffron is taken with milk twice a day for one week.
  8. Saffron improves digestion and appetite.
  9. To get relief from dry cough one should drink one hot glass of milk added with turmeric, and few strands of saffron.
  10. Saffron in paste form is applied topically for head-ache.
  11. Its external application is also useful in sores, bruises and skin diseases. It is applied on face for improving complexion and treating hyper-pigmented spots.
  12. It is also used for patchy loss of hair. For this purpose a paste of liquorice (mulethi) made by grinding the pieces in milk with a pinch of saffron is applied over the bald patches in the night before going to bed.
  13. A famous Ayurvedic preparation containing Kesar or saffron is kumkumadi tailam. This medicated saffron/kumkum oil is applied on pimples marks, dark spots, dark circles, wrinkles etc.

The recommended doses of Saffron below one gram. Toxic dose is 1.5g–5 g.

Etymology

Further information: History of saffron

A degree of uncertainty surrounds the origin of the English word, “saffron” although it can be traced to have stemmed immediately from 12th-century Old French term safran, which comes from the Latin word safranum. Safranum comes from the Persian intercessor زعفران, or za’ferân. Old Persian is the first language in which the use of saffron in cooking is recorded, with references dating back thousands of years.

Species

Main article: Crocus sativus

Description

Köhler’s Medicinal Plants:

  corolla
  stamens
  corm
  stigma

The domesticated saffron crocus, Crocus sativus, is an autumn-flowering perennial plant unknown in the wild. Its progenitors are possibly the eastern Mediterranean autumn-flowering Crocus cartwrightianus,[17][10] which is also known as “wild saffron”[18] and originated in Greece.[14] The saffron crocus probably resulted when C. cartwrightianus was subjected to extensive artificial selection by growers seeking longer stigmas. C. thomasii and C. pallasii are other possible sources.[9][10] It is a sterile triploid form, which means that three homologous sets of chromosomes compose each specimen’s genetic complement; C. sativus bears eight chromosomal bodies per set, making for 24 in total.[2] Being sterile, the purple flowers of C. sativus fail to produce viable seeds; reproduction hinges on human assistance: clusters of corms, underground, bulb-like, starch-storing organs, must be dug up, divided, and replanted. A corm survives for one season, producing via this vegetative division up to ten “cormlets” that can grow into new plants in the next season.[17] The compact corms are small, brown globules that can measure as large as 5 cm (2.0 in) in diameter, have a flat base, and are shrouded in a dense mat of parallel fibres; this coat is referred to as the “corm tunic”. Corms also bear vertical fibres, thin and net-like, that grow up to 5 cm above the plant’s neck.[2]

C. sativus.

The plant grows to a height of 20–30 cm (8–12 in), and sprouts 5–11 white and non-photosynthetic leaves known ascataphylls. These membrane-like structures cover and protect the crocus’s 5 to 11 true leaves as they bud and develop. The latter are thin, straight, and blade-like green foliage leaves, which are 1–3 mm in diameter, either expand after the flowers have opened (“hysteranthous”) or do so simultaneously with their blooming (“synanthous”).C. sativus cataphylls are suspected by some to manifest prior to blooming when the plant is irrigated relatively early in the growing season. Its floral axes, or flower-bearing structures, bear bracteoles, or specialised leaves that sprout from the flower stems; the latter are known as pedicels.[2] After aestivating in spring, the plant sends up its true leaves, each up to 40 cm (16 in) in length. In autumn, purple buds appear. Only in October, after most other flowering plants have released their seeds, do its brilliantly hued flowers develop; they range from a light pastel shade of lilac to a darker and more striated mauve.[19] The flowers possess a sweet, honey-like fragrance. Upon flowering, plants average less than 30 cm (12 in) in height.[20] A three-pronged style emerges from each flower. Each prong terminates with a vivid crimson stigma 25–30 mm (0.98–1.18 in) in length.[17]

Cultivation

Saffron bulbs for vegetative reproduction

Crocus sativus thrives in the Mediterranean maquis, an ecotype superficially resembling the North American chaparral, and similar climates where hot and dry summer breezes sweep semi-arid lands. It can nonetheless survive cold winters, tolerating frosts as low as −10 °C (14 °F) and short periods of snow cover.[17][21] Irrigation is required if grown outside of moist environments such as Kashmir, where annual rainfall averages 1,000–1,500 mm (39–59 in); saffron-growing regions in Greece (500 mm or 20 in annually) and Spain (400 mm or 16 in) are far drier than the main cultivating Iranian regions. What makes this possible is the timing of the local wet seasons; generous spring rains and drier summers are optimal. Rain immediately preceding flowering boosts saffron yields; rainy or cold weather during flowering promotes disease and reduces yields. Persistently damp and hot conditions harm the crops,[22] and rabbits, rats, and birds cause damage by digging up corms. Nematodes, leaf rusts, and corm rot pose other threats. Yet Bacillus subtilis inoculation may provide some benefit to growers by speeding corm growth and increasing stigma biomass yield.[23]

Saffron harvesting, Torbat-e Heydarieh, Iran

The plants fare poorly in shady conditions; they grow best in full sunlight. Fields that slope towards the sunlight are optimal (i.e., south-sloping in the Northern Hemisphere). Planting is mostly done in June in the Northern Hemisphere, where corms are lodged 7–15 cm (2.8–5.9 in) deep; its roots, stems, and leaves can develop between October and February.[2] Planting depth and corm spacing, in concert with climate, are critical factors in determining yields. Mother corms planted deeper yield higher-quality saffron, though form fewer flower buds and daughter corms. Italian growers optimise thread yield by planting 15 cm (5.9 in) deep and in rows 2–3 cm (0.79–1.18 in) apart; depths of 8–10 cm (3.1–3.9 in) optimise flower and corm production. Greek, Moroccan, and Spanish growers employ distinct depths and spacings that suit their locales. C. sativus prefers friable, loose, low-density, well-watered, and well-drained clay-calcareous soils with high organic content. Traditional raised beds promote good drainage. Soil organic content was historically boosted via application of some 20–30 tonnes of manure per hectare. Afterwards, and with no further manure application, corms were planted.[24] After a period of dormancy through the summer, the corms send up their narrow leaves and begin to bud in early autumn. Only in mid-autumn do they flower. Harvests are by necessity a speedy affair: after blossoming at dawn, flowers quickly wilt as the day passes.[25] All plants bloom within a window of one or two weeks.[26]Roughly 150 flowers together yield 1 g (0.035 oz) of dry saffron threads; to produce 12 g (0.42 oz) of dried saffron (or 72 g (2.5 oz) moist and freshly harvested), 1 kg (2.2 lb) of flowers are needed; 1 lb (0.45 kg) yields 0.2 oz (5.7 g) of dried saffron. One freshly picked flower yields an average 30 mg (0.0011 oz) of fresh saffron or 7 mg (0.00025 oz) dried.[24]

Spice

Chemistry

Structure of picrocrocin:[27]

  βD-glucopyranose derivative
  safranal moiety

  Picrocrocin is a monoterpene glycoside precursor of safranal. It is found in the spice saffron, which comes from the crocus flower.Picrocrocin has a bitter taste, and is the chemical most responsible for the taste of saffron. During the drying process, picrocrocin liberates the aglycone (HTCC, C10H16O2) due to the action of the enzyme glucosidase. The aglycone is then transformed to safranal by dehydration. Picrocrocin is a degradation product of the carotenoidzeaxanthin. Caballero-Ortega H, Pereda-Miranda R, Abdullaev FI (2007). “HPLC quantification of major active components from 11 different saffron (Crocus sativus L.) sources”. Food Chemistry 100 (3): 1126–1131. doi:10.1016/j.foodchem.2005.11.020.

Picrocrocin

Picrocrocin
CAS Registry Number: 138-55-6
CAS Name: (4R)-4-(b-D-Glucopyranosyloxy)-2,6,6-trimethyl-1-cyclohexene-1-carboxaldehyde
Additional Names: saffron-bitter
Molecular Formula: C16H26O7
Molecular Weight: 330.37
Percent Composition: C 58.17%, H 7.93%, O 33.90%
Literature References: From stigmas of Crocus sativus L., Iridaceae. Isoln: Kayser, Ber. 17, 2228 (1884). Structure: Kuhn, Winterstein, Ber. 67, 344 (1934). Exerts sex-determining influences in the plant organism: Kuhn, Angew. Chem. 53, 1 (1940). Its moieties are glucose and safranal, q.q.v. Abs config: Buchecker, Eugster, Helv. Chim. Acta 56, 1121 (1973). Synthesis: H. Mayer, J.-M. Santer, Helv. Chim. Acta 63, 1463 (1980).
Properties: Crystals, mp 154-156°. [a]D20 -58° (c = 0.6). Bitter taste. Alkali unstable. Sol in water, alcohol; slightly sol in chloroform, ether. Practically insol in petr ether, benzene.
Melting point: mp 154-156°
Optical Rotation: [a]D20 -58° (c = 0.6)
structure of Picrocrocin

Picrocrocin
Picrocrocin
Picrocrocin
Names
IUPAC names

4-(β-D-glucopyranosyloxy)- 2,6,6-trimethyl-1-cyclohexene- 1-carboxaldehyde
Identifiers
CAS number 138-55-6 Yes
ChemSpider 115678 
Jmol-3D images Image (138-55-6)
PubChem 130796
Properties
C16H26O7
Molar mass 330.37 g/mol
Density 1.31 g/mL
Melting point 154 to 156 °C (309 to 313 °F; 427 to 429 K)
Boiling point 520.4 °C (968.7 °F; 793.5 K)
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)

The chemical structure of the main bioactive compounds from the dried stigmas of Crocus sativus L. – See more at: http://www.mdpi.com/2304-8158/3/3/403/htm#sthash.iOWsNDGb.dpuf Foods 03 00403 g001 1024

Saffron contains more than 150 volatile and aroma-yielding compounds. It also has many nonvolatile active components,[28] many of which are carotenoids, including zeaxanthin, lycopene, and various α- and β-carotenes. However, saffron’s golden yellow-orange colour is primarily the result of α-crocin. This crocin is trans-crocetin di-(β-D-gentiobiosyl) ester; it bears the systematic (IUPAC) name 8,8-diapo-8,8-carotenoic acid. This means that the crocin underlying saffron’s aroma is a digentiobiose ester of the carotenoid crocetin.[28] Crocins themselves are a series ofhydrophilic carotenoids that are either monoglycosyl or diglycosyl polyene esters of crocetin.[28] Crocetin is a conjugated polyene dicarboxylic acidthat is hydrophobic, and thus oil-soluble. When crocetin is esterified with two water-soluble gentiobioses, which are sugars, a product results that is itself water-soluble. The resultant α-crocin is a carotenoid pigment that may comprise more than 10% of dry saffron’s mass. The two esterified gentiobioses make α-crocin ideal for colouring water-based and non-fatty foods such as rice dishes.[7]

Esterification reaction betweencrocetin and gentiobiose. Components of α–crocin:

  βD-gentiobiose
  crocetin

The bitter glucoside picrocrocin is responsible for saffron’s flavour. Picrocrocin (chemical formula:C 16H 26O 7; systematic name: 4-(β-D-glucopyranosyloxy)-2,6,6- trimethylcyclohex-1-ene-1-carboxaldehyde) is a union of an aldehyde sub-element known as safranal (systematic name: 2,6,6-trimethylcyclohexa-1,3-diene-1-carboxaldehyde) and a carbohydrate. It has insecticidal and pesticidal properties, and may comprise up to 4% of dry saffron. Picrocrocin is a truncated version of the carotenoidzeaxanthin that is produced via oxidative cleavage, and is the glycoside of the terpene aldehyde safranal. The reddish-coloured zeaxanthin is, incidentally, one of the carotenoids naturally present within the retina of the human eye.[29] When saffron is dried after its harvest, the heat, combined with enzymatic action, splits picrocrocin to yield Dglucose and a free safranal molecule.[27] Safranal, a volatile oil, gives saffron much of its distinctive aroma.[13][30] Safranal is less bitter than picrocrocin and may comprise up to 70% of dry saffron’s volatile fraction in some samples.[29] A second element underlying saffron’s aroma is 2-hydroxy-4,4,6-trimethyl-2,5-cyclohexadien-1-one, which produces a scent described as saffron, dried hay-like.[31] Chemists find this is the most powerful contributor to saffron’s fragrance, despite its presence in a lesser quantity than safranal.[31] Dry saffron is highly sensitive to fluctuating pH levels, and rapidly breaks down chemically in the presence of light andoxidising agents. It must, therefore, be stored away in air-tight containers to minimise contact with atmospheric oxygen. Saffron is somewhat more resistant to heat.

Grades and ISO 3632 categories[edit]

Red threads and yellow styles.

Saffron is not all of the same quality and strength. Strength is related to several factors including the amount of style picked along with the red stigma. Age of the saffron is also a factor. More style included means the saffron is less strong gram for gram, because the colour and flavour are concentrated in the red stigmas. Saffron from Iran, Spain and Kashmir is classified into various grades according to the relative amounts of red stigma and yellow styles it contains. Grades of Iranian saffron are: “sargol” (red stigma tips only, strongest grade), “pushal” or “pushali” (red stigmas plus some yellow style, lower strength), “bunch” saffron (red stigmas plus large amount of yellow style, presented in a tiny bundle like a miniature wheatsheaf) and “konge” (yellow style only, claimed to have aroma but with very little, if any, colouring potential). Grades of Spanish saffron are “coupé” (the strongest grade, like Iranian sargol), “mancha” (like Iranian pushal), and in order of further decreasing strength “rio”, “standard” and “sierra” saffron. The word “mancha” in the Spanish classification can have two meanings: a general grade of saffron or a very high quality Spanish-grown saffron from a specific geographical origin. Real Spanish-grown La Mancha saffron has PDO protected status and this is displayed on the product packaging. Spanish growers fought hard for Protected Status because they felt that imports of Iranian saffron re-packaged in Spain and sold as “Spanish Mancha saffron” were undermining the genuine La Mancha brand. Countries producing less saffron do not have specialised words for different grades and may only produce one grade. Artisan producers in Europe and New Zealand have offset their higher labour charges for saffron harvesting by targeting quality, only offering extremely high grade saffron. In addition to descriptions based on how the saffron is picked, saffron may be categorised under the international standard ISO 3632 after laboratory measurement of crocin (responsible for saffron’s colour), picrocrocin (taste), and safranal (fragrance or aroma) content.[32] However, often there is no clear grading information on the product packaging and little of the saffron readily available in UK is labelled with ISO category. This lack of information makes it hard for customers to make informed choices when comparing prices and buying saffron. Under ISO 3632, determination of non-stigma content (“floral waste content”) and other extraneous matter such as inorganic material (“ash“) are also key. Grading standards are set by the International Organization for Standardization, a federation of national standards bodies. ISO 3632 deals exclusively with saffron and establishes three categories: III (poorest quality), II, and I (finest quality). Formerly there was also category IV, which was below category III. Samples are assigned categories by gauging the spice’s crocin and picrocrocin content, revealed by measurements of specific spectrophotometric absorbance. Safranal is treated slightly differently and rather than there being threshold levels for each category, samples must give a reading of 20-50 for all categories. These data are measured through spectrophotometry reports at certified testing laboratories worldwide. Higher absorbances imply greater levels of crocin, picrocrocin and safranal, and thus a greater colouring potential and therefore strength per gram. The absorbance reading of crocin is known as the “colouring strength” of that saffron. Saffron’s colouring strength can range from lower than 80 (for all category IV saffron) up to 200 or greater (for category I). The world’s finest samples (the selected, most red-maroon, tips of stigmas picked from the finest flowers) receive colouring strengths in excess of 250, making such saffron over three times more powerful than category IV saffron. Market prices for saffron types follow directly from these ISO categories. Sargol and coupé saffron would typically fall into ISO 3632 category I. Pushal and mancha would probably be assigned to category II. On many saffron packaging labels, neither the ISO 3632 category nor the colouring strength (the measurement of crocin content) is displayed. However, many growers, traders, and consumers reject such lab test numbers. Some people prefer a more holistic method of sampling batches of threads for taste, aroma, pliability, and other traits in a fashion similar to that practised by experienced wine tasters.[33] However, ISO 3632 grade and colouring strength information allow consumers to make instant comparisons between the quality of different saffron brands, without needing to purchase and sample the saffron. In particular, consumers can work out value for money based on price per unit of colouring strength rather than price per gram, given the wide possible range of colouring strengths that different kinds of saffron can have. Despite attempts at quality control and standardisation, an extensive history of saffron adulteration, particularly among the cheapest grades, continues into modern times. Adulteration was first documented in Europe’s Middle Ages, when those found selling adulterated saffron were executed under the Safranschou code.[34] Typical methods include mixing in extraneous substances like beets, pomegranate fibres, red-dyed silk fibres, or the saffron crocus’s tasteless and odourless yellow stamens. Other methods included dousing saffron fibres with viscid substances like honey or vegetable oil to increase their weight. However, powdered saffron is more prone to adulteration, with turmeric, paprika, and other powders used as diluting fillers. Adulteration can also consist of selling mislabelled mixes of different saffron grades. Thus, in India, high-grade Kashmiri saffron is often sold and mixed with cheaper Iranian imports; these mixes are then marketed as pure Kashmiri saffron, a development that has cost Kashmiri growers much of their income.[35][36]

Types

Saffron from different producer countries, picked and dried in different ways gives rise to different end qualities.

The various saffron crocus cultivars give rise to thread types that are often regionally distributed and characteristically distinct. Varieties (not varieties in the botanical sense) from Spain, including the tradenames “Spanish Superior” and “Creme”, are generally mellower in colour, flavour, and aroma; they are graded by government-imposed standards. Italian varieties are slightly more potent than Spanish. The most intense varieties tend to be Iranian. Various “boutique” crops are available from New Zealand, France, Switzerland, England, the United States, and other countries—some of them organically grown. In the U.S., Pennsylvania Dutch saffron—known for its “earthy” notes—is marketed in small quantities.[37][38] Consumers may regard certain cultivars as “premium” quality. The “Aquila” saffron, or zafferano dell’Aquila, is defined by high safranal and crocin content, distinctive thread shape, unusually pungent aroma, and intense colour; it is grown exclusively on eight hectares in the Navelli Valley of Italy’s Abruzzo region, near L’Aquila. It was first introduced to Italy by a Dominican monk from Inquisition-era Spain. But the biggest saffron cultivation in Italy is in San Gavino Monreale, Sardinia, where it is grown on 40 hectares, representing 60% of Italian production; it too has unusually high crocin, picrocrocin, and safranal content. Another is the “Mongra” or “Lacha” saffron of Kashmir (Crocus sativus ‘Cashmirianus’), which is among the most difficult for consumers to obtain. Repeated droughts, blights, and crop failures in the Indian-controlled areas of Kashmir combine with an Indian export ban to contribute to its prohibitive overseas prices. Kashmiri saffron is recognisable by its dark maroon-purple hue; it is among the world’s darkest, which hints at strong flavour, aroma, and colouring effect.

History

Main article: History of saffron

A detail from the “Saffron Gatherers” fresco of the “Xeste 3” building. It is one of many depicting saffron; they were found at the Bronze Age settlement ofAkrotiri, on the Aegean island of Santorini.

The documented history of saffron cultivation spans more than three millennia.[17] The wild precursor of domesticated saffron crocus wasCrocus cartwrightianus. Human cultivators bred wild specimens by selecting for unusually long stigmas; thus, a sterile mutant form of C. cartwrightianus, C. sativus, likely emerged in late Bronze Age Crete.[12]

Eastern

Buddhist adepts pray in the Hundred Dragons Hall, Buddha Tooth Relic Temple and Museum, Singapore, wearing saffron-coloured robes.

Saffron was detailed in a 7th-century BC Assyrian botanical reference compiled under Ashurbanipal.[15]Documentation of saffron’s use over the span of 4,000 years in the treatment of some 90 illnesses has been uncovered.[39] Saffron-based pigments have indeed been found in 50,000 year-old depictions of prehistoric places in northwest Iran.[40][41] The Sumerians later used wild-growing saffron in their remedies and magical potions.[42] Saffron was an article of long-distance trade before the Minoan palace culture’s 2nd millennium BC peak. Ancient Persians cultivated Persian saffron (Crocus sativus ‘Hausknechtii’) in Derbena, Isfahan, and Khorasan by the 10th century BC. At such sites, saffron threads were woven into textiles,[40] ritually offered to divinities, and used in dyes, perfumes, medicines, and body washes.[43]Saffron threads would thus be scattered across beds and mixed into hot teas as a curative for bouts of melancholy. Non-Persians also feared the Persians’ usage of saffron as a drugging agent and aphrodisiac.[44] During his Asian campaigns, Alexander the Great used Persian saffron in his infusions, rice, and baths as a curative for battle wounds. Alexander’s troops imitated the practice from the Persians and brought saffron-bathing to Greece.[45] Conflicting theories explain saffron’s arrival in South Asia. Kashmiri and Chinese accounts date its arrival anywhere between 2500–900 years ago.[46][47][48] Historians studying ancient Persian records date the arrival to sometime prior to 500 BC,[7] attributing it to a Persian transplantation of saffron corms to stock new gardens and parks.[49] Phoenicians then marketed Kashmiri saffron as a dye and a treatment for melancholy. Its use in foods and dyes subsequently spread throughout South Asia. Buddhist monks wear saffron-coloured robes; however, the robes are not dyed with costly saffron but turmeric, a less expensive dye, or jackfruit.[50] Monks’ robes are dyed the same colour to show equality with each other, and turmeric or ochre were the cheapest, most readily available dyes. Gamboge is now used to dye the robes.[51] Some historians believe that saffron came to China with Mongol invaders from Persia.[52] Yet saffron is mentioned in ancient Chinese medical texts, including the forty-volume pharmacopoeia titled Shennong Bencaojing (神農本草經: “Shennong’s Great Herbal”, also known as Pen Ts’ao or Pun Tsao), a tome dating from 300–200 BC. Traditionally credited to the fabled Yan (“Fire”) Emperor (炎帝) Shennong, it discusses 252 phytochemical-based medical treatments for various disorders.[53] Nevertheless, around the 3rd century AD, the Chinese were referring to saffron as having a Kashmiri provenance. According to Chinese herbalist Wan Zhen, “[t]he habitat of saffron is in Kashmir, where people grow it principally to offer it to the Buddha.” Wan also reflected on how it was used in his time: “The flower withers after a few days, and then the saffron is obtained. It is valued for its uniform yellow colour. It can be used to aromatise wine.”[48]

Wider Near East, Western Europe and the USA

Preserved “safran”, Staatliches Museum für Naturkunde, Karlsruhe, Germany.

The Minoans portrayed saffron in their palace frescoes by 1600–1500 BC; they hint at its possible use as a therapeutic drug.[39][54] Ancient Greek legends told of sea voyages to Cilicia, where adventurers sought what they believed were the world’s most valuable threads.[21] Another legend tells of Crocus and Smilax, whereby Crocus is bewitched and transformed into the first saffron crocus.[40] Ancient perfumers in Egypt, physicians inGaza, townspeople in Rhodes,[55] and the Greek hetaerae courtesans used saffron in their scented waters, perfumes and potpourris, mascaras and ointments, divine offerings, and medical treatments.[44] In late Hellenistic Egypt, Cleopatra used saffron in her baths so that lovemaking would be more pleasurable.[56] Egyptian healers used saffron as a treatment for all varieties of gastrointestinal ailments.[57] Saffron was also used as a fabric dye in such Levantine cities as Sidon and Tyre inLebanon.[58] Aulus Cornelius Celsus prescribes saffron in medicines for wounds, cough, colic, and scabies, and in the mithridatium.[59] Such was the Romans’ love of saffron that Roman colonists took it with them when they settled in southern Gaul, where it was extensively cultivated until Rome’s fall. Competing theories state that saffron only returned to France with 8th-century AD Moors or with the Avignon papacy in the 14th century AD.[60] European saffron cultivation plummeted after the Roman Empire went into eclipse. As with France, the spread of Islamic civilisation may have helped reintroduce the crop to Spain and Italy.[61] The 14th-century Black Death caused demand for saffron-based medicaments to peak, and Europe imported large quantities of threads via Venetian and Genoan ships from southern and Mediterranean lands such as Rhodes. The theft of one such shipment by noblemen sparked the fourteen-week-long Saffron War.[62] The conflict and resulting fear of rampant saffron piracy spurred corm cultivation in Basel; it thereby grew prosperous.[63] The crop then spread to Nuremberg, where endemic and insalubrious adulteration brought on the Safranschou code—whereby culprits were variously fined, imprisoned, and executed.[64] Saffron cultivation was introduced into England in around 1350, the story being that corms were smuggled from the Levant in a special hollow compartment of a pilgrim’s staff .[65]The crop seems to have been initially grown in monastic gardens for medicinal use, only being planted in the less kind conditions of open fields many decades later. Soil and climatic conditions meant that by the sixteenth century, saffron cultivation had centred on Eastern England. The Essex town of Saffron Walden, named for its new speciality crop, emerged as a prime saffron growing and trading centre. However, an important omission in a botanical book published in the 1790s meant that the true extent of saffron growing in the eastern counties has been long overlooked .[66] North Norfolk (especially the area around Walsingham), southern Cambridgeshire and a small area of west Suffolk also produced saffron. Some was also grown in Gloucestershire and other “Westerlie Parts” according to one source. The evidence for this comes from several angles including titherecords, estate records and field names. In Norfolk, customs records show locally grown saffron was exported to the Low Countries .[67] (The crop has recently been re-introduced to Norfolk and award-winning ISO 3632 category I saffron is grown at Burnham Norton. However, an influx of more exotic spices—chocolate, coffee, tea, and vanilla—from newly contacted Eastern and overseas countries caused European cultivation and usage of saffron to decline.[68][69] The last grower in England appears to have been John Knott of Duxford in Cambridgeshire, who delivered his crop to London apothecaries until around 1818 .[70] It would be nearly two centuries before saffron was commercially grown in England again. Only in southern France, Italy, and Spain did the clone significantly endure.[71] Europeans introduced saffron to the Americas when immigrant members of the Schwenkfelder Church left Europe with a trunk containing its corms. Church members had grown it widely in Europe.[37] By 1730, the Pennsylvania Dutch cultivated saffron throughout eastern Pennsylvania. Spanish colonies in the Caribbean bought large amounts of this new American saffron, and high demand ensured that saffron’s list price on the Philadelphia commodities exchange was equal to gold.[72] Trade with the Caribbean later collapsed in the aftermath of the War of 1812, when many saffron-bearing merchant vessels were destroyed.[73] Yet the Pennsylvania Dutch continued to grow lesser amounts of saffron for local trade and use in their cakes, noodles, and chicken or trout dishes.[74] American saffron cultivation survives into modern times, mainly in Lancaster County, Pennsylvania.[37]

Trade and use

Saffron (Crocus sativus L.)
Nutritional value per 100 g (3.5 oz)
Energy 1,298 kJ (310 kcal)
65.37 g
Dietary fibre 3.9 g
5.85 g
Saturated 1.586 g
Monounsaturated 0.429 g
Polyunsaturated 2.067 g
11.43 g
Vitamins
Vitamin A 530 IU
Thiamine (B1)
(10%)

0.115 mg

Riboflavin (B2)
(22%)

0.267 mg

Niacin (B3)
(10%)

1.460 mg

Vitamin C
(97%)

80.8 mg

Trace metals
Calcium
(11%)

111 mg

Iron
(85%)

11.10 mg

Magnesium
(74%)

264 mg

Phosphorus
(36%)

252 mg

Potassium
(37%)

1724 mg

Sodium
(10%)

148 mg

Zinc
(11%)

1.09 mg

Other constituents
Water 11.90 g
Selenium 5.6 μg
Folate[N 1] 93 μg
Vitamin B6 1.010 mg
Ash 5.45 g

Edible thread portion only.[75]
Percentages are roughly approximated usingUS recommendations for adults. Source: USDA Nutrient Database

Trade

“Ispanya saffron” at market in Turkey.

Sale of saffron and other spices in Iran

Almost all saffron grows in a belt from Spain in the west to India in the east. The other continents, except Antarctica, produce smaller amounts. Some 300 t (300,000 kg) of dried whole threads and powder are gleaned yearly,[14] of which 50 t (50,000 kg) is top-grade “coupe” saffron.[76] Iran answers for around 90–93% of global production and exports much of it.[16] A few of Iran’s drier eastern and southeastern provinces, including Fars, Kerman, and those in the Khorasan region, glean the bulk of modern global production. In 2005, the second-ranked Greece produced 5.7 t (5,700 kg), while Morocco and Kashmir, tied for third rank, each produced 2.3 t (2,300 kg).[16] In recent years, Afghan cultivation has risen. Azerbaijan, Morocco, and Italy are, in decreasing order, lesser producers. Prohibitively high labour costs and abundant Iranian imports mean that only select locales continue the tedious harvest in Austria, Germany, and Switzerland—among them the Swiss village of Mund, whose annual output is a few kilograms.[14] Microscale production of saffron can be found in Tasmania,[77] China, Egypt, England (the village of Burnham Norton[78]) France, Israel, Mexico, New Zealand, Turkey (mainly around the town of Safranbolu), California, and Central Africa.[4][28] To glean 1 lb (450 g) of dry saffron requires the harvest of 50,000–75,000 flowers; a kilogram requires 110,000–170,000 flowers.[79][80] Forty hours of labour are needed to pick 150,000 flowers.[81] Stigmas are dried quickly upon extraction and (preferably) sealed in airtight containers.[82] Saffron prices at wholesale and retail rates range from US$500 to US$5,000 per pound, or US$1,100–11,000/kg, equivalent to £2,500/€3,500 per pound or £5,500/€7,500 per kilogram. In Western countries, the average retail price in 1974 was $1,000/£500/€700 per pound, or US$2,200/£1,100/€1,550 per kilogram.[4] In February 2013, a retail bottle containing 0.06 ounces could be purchased for $16.26 or the equivalent of $4,336 per pound or as little as about $2,000/pound in larger quantities. A pound contains between 70,000 and 200,000 threads. Vivid crimson colouring, slight moistness, elasticity, and lack of broken-off thread debris are all traits of fresh saffron.

Use

Crushed saffron threads are soaked in hot—but not boiling—water for several minutes prior to use in cuisine. This helps release the beneficial components.

Saffron’s aroma is often described by connoisseurs as reminiscent of metallic honey with grassy or hay-like notes, while its taste has also been noted as hay-like and sweet. Saffron also contributes a luminous yellow-orange colouring to foods. Saffron is widely used in Indian, Persian, European, Arab, and Turkish cuisines. Confectioneries and liquors also often include saffron. Common saffron substitutes include safflower (Carthamus tinctorius, which is often sold as “Portuguese saffron” or “açafrão”), annatto, and turmeric (Curcuma longa). Saffron has also been used as a fabric dye, particularly in China and India, and in perfumery.[83] It is used for religious purposes in India, and is widely used in cooking in many cuisines, ranging from the Milanese risotto of Italy to the bouillabaisse of France to the biryani with various meat accompaniments in South Asia. Saffron also has a long history of use in traditional medicine.[84]

Biomedical research

There is some evidence to suggest that saffron may help alleviate the symptoms of major depressive disorder.[85][86] Preclinical studies indicate that saffron could be a promising candidate for cancer chemoprevention studies.[87] Early studies suggest that it may protect the eye from the direct effects of bright light, and from retinal stress in additional to slowing down macular degeneration and retinitis pigmentosa.[88] (Most saffron-related research refers to the stigmas, but this is often not made explicit in research papers.) Some studies suggest that saffron may help relieve the symptoms of premenstrual syndrome.[89][90]

Notes

  1.  “Folate” refers only to the naturally occurring form of folic acid; the sample contains no folic acid per se.[75]

Citations

  1.  “Saffron – Definition and More”. Merriam-Webster. Retrieved 21 November 2012.
  2.  Kafi et al. 2006, p. 23.
  3.  Rau 1969, p. 53.
  4.  Hill 2004, p. 272.
  5.  “World’s COSTLIEST spice blooms in Kashmir”.Rediff. Retrieved 7 January 2013.
  6.  Grigg 1974, p. 287.
  7. McGee 2004, p. 422.
  8.  Rubio-Moraga et al. 2009.
  9. ^ Jump up to:a b Negbi 1999, p. 28.
  10. ^ Jump up to:a b c d Caiola 2003, p. 1.
  11. Jump up^ Negbi 1999, p. 30–31.
  12. ^ Jump up to:a b Negbi 1999, p. 1.
  13. ^ Jump up to:a b McGee 2004, p. 423.
  14. ^ Jump up to:a b c d Katzer 2010.
  15. ^ Jump up to:a b Russo, Dreher & Mathre 2003, p. 6.
  16. ^ Jump up to:a b c Ghorbani 2008, p. 1.
  17.  Deo 2003, p. 1.
  18. Jump up^ Kafi et al. 2006, p. 24.
  19.  Willard 2002, p. 3.
  20. Jump up^ Government of Tasmania 2005.
  21. ^ Jump up to:a b Willard 2002, pp. 2–3.
  22. Jump up^ Deo 2003, p. 2.
  23. Jump up^ Sharaf-Eldin et al. 2008.
  24. ^ Jump up to:a b Deo 2003, p. 3.
  25. Jump up^ Willard 2002, pp. 3–4.
  26. Jump up^ Willard 2002, p. 4.
  27. ^ Jump up to:a b Deo 2003, p. 4.
  28. ^ Jump up to:a b c d Abdullaev 2002, p. 1.
  29. ^ Jump up to:a b Leffingwell 2002, p. 1.
  30. Jump up^ Dharmananda 2005.
  31. ^ Jump up to:a b Leffingwell 2002, p. 3.
  32. Jump up^ Verma & Middha 2010, p. 1–2.
  33. Jump up^ Hill 2004, p. 274.
  34. Jump up^ Willard 2002, pp. 102–104.
  35. Jump up^ Australian Broadcasting Corp. 2003.
  36. Jump up^ Hussain 2005.
  37. ^ Jump up to:a b c Willard 2002, p. 143.
  38. Jump up^ Willard 2002, p. 201.
  39. ^ Jump up to:a b Honan 2004.
  40. ^ Jump up to:a b c Willard 2002, p. 2.
  41. Jump up^ Humphries 1998, p. 20.
  42. Jump up^ Willard 2002, p. 12.
  43. Jump up^ Willard 2002, pp. 17–18.
  44. ^ Jump up to:a b Willard 2002, p. 41.
  45. Jump up^ Willard 2002, pp. 54–55.
  46. Jump up^ Lak 1998b.
  47. Jump up^ Fotedar 1999, p. 128.
  48. ^ Jump up to:a b Dalby 2002, p. 95.
  49. Jump up^ Dalby 2003, p. 256.
  50. Jump up^ Finlay 2003, p. 224.
  51. Jump up^ Hanelt 2001, p. 1352.
  52. Jump up^ Fletcher 2005, p. 11.
  53. Jump up^ Hayes 2001, p. 6.
  54. Jump up^ Ferrence & Bendersky 2004, p. 1.
  55. Jump up^ Willard 2002, p. 58.
  56. Jump up^ Willard 2002, p. 55.
  57. Jump up^ Willard 2002, pp. 34–35.
  58. Jump up^ Willard 2002, p. 59.
  59. Jump up^ Marx 1989.
  60. Jump up^ Willard 2002, p. 63.
  61. Jump up^ Willard 2002, p. 70.
  62. Jump up^ Willard 2002, p. 99.
  63. Jump up^ Willard 2002, p. 101.
  64. Jump up^ Willard 2002, pp. 103–104.
  65. Jump up^ Francis 2011, p. 17.
  66. Jump up^ Francis 2011, p. 21.
  67. Jump up^ Francis 2011, p. 33.
  68. Jump up^ Willard 2002, p. 117.
  69. Jump up^ Willard 2002, pp. 132–133.
  70. Jump up^ Francis 2011, p. 36.
  71. Jump up^ Willard 2002, p. 133.
  72. Jump up^ Willard 2002, p. 138.
  73. Jump up^ Willard 2002, pp. 138–139.
  74. Jump up^ Willard 2002, pp. 142–146.
  75. ^ Jump up to:a b United States Department of Agriculture.
  76. Jump up^ Negbi 1999, p. 2.
  77. Jump up^ Courtney 2002.
  78. Jump up^ “Norfolk Saffron; England’s ‘red gold’”. Our Norfolk. Retrieved 22 January 2015.
  79. Jump up^ Hill 2004, p. 273.
  80.  Rau 1969, p. 35.
  81. Jump up^ Lak 1998a.
  82.  Negbi 1999, p. 8.
  83. Jump up^ Dalby 2002, p. 138.
  84.  Mousavi, S. Z.; Bathaie, S. Z. (2011). “Historical uses of saffron: Identifying potential new avenues for modern research”. Avicenna Journal of Phytomedicine 1 (2): 27–66.
  85. Jump up^ Hausenblas HA, Saha D, Dubyak PJ, Anton SD (November 2013). “Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials”. Journal of Integrative Medicine 11 (6): 377–83. doi:10.3736/jintegrmed2013056.PMID 24299602.
  86.  Lopresti AL, Drummond PD (2014). “Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action”. Human Psychopharmacology: Clinical and Experimental. doi:10.1002/hup.2434.
  87.  Zhang Z, Wang CZ, Wen XD, Shoyama Y, Yuan CS (July 2013). “Role of saffron and its constituents on cancer chemoprevention”. Pharmaceutical Biology 51(7): 920–4. doi:10.3109/13880209.2013.771190.PMC 3971062. PMID 23570520.
  88.  Maccarone, Di Marco & Bisti 2008.
  89.  Moghaddasi 2010.
  90.  Dante G, Facchinetti F (March 2011). “Herbal treatments for alleviating premenstrual symptoms: a systematic review”. Journal of Psychosomatic Obstetrics and Gynaecology 32 (1): 42–51.doi:10.3109/0167482X.2010.538102.PMID 21171936.

References

Books

Journal articles

  • Abdullaev, F. I. (2002), “Cancer Chemopreventive and Tumoricidal Properties of Saffron (Crocus sativus L.)”, Experimental Biology and Medicine 227 (1), PMID 11788779, retrieved 11 September 2011
  • Agha-Hosseini, M.; Kashani, L.; Aleyaseen, A.; Ghoreishi, A.; Rahmanpour, H.; Zarrinara, A. R.; Akhondzadeh, S. (2008), “Crocus sativus L. (Saffron) in the Treatment of Premenstrual Syndrome: A Double-Blind, Randomised, and Placebo-Controlled Trial”, BJOG: An International Journal of Obstetrics and Gynaecology 115 (4): 515–519, doi:10.1111/j.1471-0528.2007.01652.x, PMID 18271889
  • Akhondzadeh, S.; Sabet, M. S.; Harirchian, M. H.; Togha, M.; Cheraghmakani, H.; Razeghi, S.; Hejazi, S. S.; Yousefi, M.H.; Alimardani, R.; Jamshidi, A.; Zare, F.; Moradi, A. (2010), “Saffron in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease: A 16-week, Randomised, and Placebo-Controlled Trial”, Journal of Clinical Pharmacy and Therapeutics 35(5): 581–588, doi:10.1111/j.1365-2710.2009.01133.x, PMID 20831681
  • Assimopoulou, A. N.; Papageorgiou, V. P.; Sinakos, Z. (2005), “Radical Scavenging Activity ofCrocus sativus L. Extract and Its Bioactive Constituents”, Phytotherapy Research 19 (11),doi:10.1002/ptr.1749, PMID 16317646
  • Boskabady, M. H.; Ghasemzadeh Rahbardar, M.; Nemati, H.; Esmaeilzadeh, M. (2010), “Inhibitory Effect of Crocus sativus (Saffron) on Histamine (H1) Receptors of Guinea Pig Tracheal Chains”, Die Pharmazie 65 (4): 300–305, PMID 20432629
  • Caiola, M. G. (2003), “Saffron Reproductive Biology”, Acta Horticulturae (ISHS) 650: 25–37
  • Chang, P. Y.; Kuo, W.; Liang, C. T.; Wang, C. K. (1964), “The Pharmacological Action of 藏红花 (Zà Hóng HuāCrocus sativus L.): Effect on the Uterus and Estrous Cycle”, Yao Hsueh Hsueh Pao 11
  • Chryssanthi, D. G.; Dedes, P. G.; Karamanos, N. K.; Cordopatis, P.; Lamari, F. N. (2011), “Crocetin Inhibits Invasiveness of MDA-MB-231 Breast Cancer Cells via Downregulation of Matrix Metalloproteinases”, Planta Medica 77 (2): 146–151, doi:10.1055/s-0030-1250178,PMID 20803418
  • Das, I.; Das, S.; Saha, T. (2010), “Saffron Suppresses Oxidative Stress in DMBA-Induced Skin Carcinoma: A Histopathological Study”, Acta Histochemica 112 (4): 317–327,doi:10.1016/j.acthis.2009.02.003, PMID 19328523
  • Davies, N. W.; Gregory, M. J.; Menary, R. C. (2005), “Effect of Drying Temperature and Air Flow on the Production and Retention of Secondary Metabolites in Saffron”, Journal of Agricultural and Food Chemistry 53 (15): 5969–5975, doi:10.1021/jf047989j,PMID 16028982
  • Deo, B. (2003), “Growing Saffron—The World’s Most Expensive Spice”, Crop and Food Research (New Zealand Institute for Crop and Food Research) (20), archived from the original on 27 December 2005, retrieved 10 January 2006
  • Dharmananda, S. (2005), “Saffron: An Anti-Depressant Herb”, Institute for Traditional Medicine, archived from the original on 26 September 2006, retrieved 10 January 2006
  • Ferrence, S. C.; Bendersky, G. (2004), “Therapy with Saffron and the Goddess at Thera”,Perspectives in Biology and Medicine 47 (2): 199–226, doi:10.1353/pbm.2004.0026,PMID 15259204
  • Ghorbani, M. (2008), “The Efficiency of Saffron’s Marketing Channel in Iran”, World Applied Sciences Journal 4 (4): 523–527, ISSN 1818-4952, retrieved 3 October 2011
  • Gout, B.; Bourges, C.; Paineau-Dubreuil, S. (2010), “Satiereal, a Crocus sativus L. Extract, Reduces Snacking and Increases Satiety in a Randomised Placebo-Controlled Study of Mildly Overweight, Healthy Women”, Nutrition Research 30 (5): 305–313,doi:10.1016/j.nutres.2010.04.008, PMID 20579522
  • Gutheil, W. G.; Reed, G.; Ray, A.; Dhar, A. (2011), “Crocetin: An Agent Derived from Saffron for Prevention and Therapy for Cancer”, Current Pharmaceutical Biotechnology,PMID 21466430
  • Hasegawa, J. H.; Kurumboor, S. K.; Nair, S. C. (1995), “Saffron Chemoprevention in Biology and Medicine: A Review”, Cancer Biotherapy 10 (4), PMID 8590890
  • Hausenblas, H. A.; Saha, D.; Dubyakt, P. A.; Anton, P. J. (2013), “Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials”, Journal of Integrative Medicine 11 (6), doi:10.3736/jintegrmed2013056, PMID 24299602
  • Hosseinzadeh, H.; Karimi, G.; Niapoor, M. (2004), “Antidepressant Effect of Crocus sativus L. Stigma Extracts and Their Constituents, Crocin and Safranal, In Mice”, Acta Horticulturae(International Society for Horticultural Science) (650): 435–445, retrieved 23 November 2009
  • Jessie, S. W.; Krishnakantha, T. P. (2005), “Inhibition of Human Platelet Aggregation and Membrane Lipid Peroxidation by Saffron”, Molecular and Cellular Biochemistry 278 (1–2): 59–63, doi:10.1007/s11010-005-5155-9, PMID 16180089
  • Joukar, S.; Najafipour, H.; Khaksari, M.; Sepehri, G.; Shahrokhi, N.; Dabiri, S.; Gholamhoseinian, A.; Hasanzadeh, S. (2010), “The Effect of Saffron Consumption on Biochemical and Histopathological Heart Indices of Rats with Myocardial Infarction”,Cardiovascular Toxicology 10 (1): 66–71, doi:10.1007/s12012-010-9063-1,PMID 20119744
  • Kianbakht, S.; Ghazavi, A. (2011), “Immunomodulatory Effects of Saffron: A Randomized Double-Blind Placebo-Controlled Clinical Trial”, Phytotherapy Research,doi:10.1002/ptr.3484, PMID 21480412
  • Lopresti, A. L.; Drummond, P. D. (2014), “Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action”,Human Psychopharmacology: Clinical and Experimental, doi:10.1002/hup.2434
  • Moghaddasi, M. S. (2010), “Saffron Chemicals and Medicine Usage” (PDF), Journal of Medicinal Plant Research 4 (6): 427–430, retrieved 30 September 2011
  • Maccarone, R.; Di Marco, S.; Bisti, S. (2008), “Saffron Supplement Maintains Morphology and Function after Exposure to Damaging Light in Mammalian Retina”, Investigative Ophthalmology and Visual Science 49 (3): 1254–1261, doi:10.1167/iovs.07-0438,PMID 18326756
  • Nair, S. C.; Pannikar, B.; Panikkar, K. R. (1991), “Antitumour Activity of Saffron (Crocus sativus).”, Cancer Letters 57 (2), doi:10.1016/0304-3835(91)90203-T, PMID 2025883
  • Rubio-Moraga, A.; Castillo-López, R.; Gómez-Gómez, L.; Ahrazem, O. (2009), “Saffron is a Monomorphic Species as Revealed by RAPD, ISSR and Microsatellite Analyses”, BMC Research Notes 2: 189, doi:10.1186/1756-0500-2-189, PMC 2758891, PMID 19772674
  • Sharaf-Eldin, M.; Elkholy, S.; Fernández, J. A.; Junge, H.; Cheetham, R.; Guardiola, J.; Weathers, P. (2008), “Bacillus subtilis FZB24 Affects Flower Quantity and Quality of Saffron (Crocus sativus)”, Planta Med 74 (10): 1316–1320, doi:10.1055/s-2008-1081293,PMC 3947403, PMID 18622904
  • Verma, R. S.; Middha, D. (2010), “Analysis of Saffron (Crocus sativus L. Stigma) Components by LC–MS–MS”, Chromatographia 71 (1–2): 117–123, doi:10.1365/s10337-009-1398-z

Miscellaneous

Other

External links

Contraindications, Interactions, and Side Effects (Saffron)

Saffron use in large dose is contraindicated in pregnancy. It may cause contraction of uterus and abortion. Severe side effects may result from ingesting 5 g saffron. No side-effect when used in proper doses.

Quality by Design in Action 1: Controlling Critical Quality Attributes of an Active Pharmaceutical Ingredient


DR ANTHONY MELVIN CRASTO Ph.D's avatarDRUG REGULATORY AFFAIRS INTERNATIONAL

Abstract Image

The importance of Quality by Design (QbD) is being realized gradually, as it is gaining popularity among the generic companies. However, the major hurdle faced by these industries is the lack of common guidelines or format for performing a risk-based assessment of the manufacturing process. This article tries to highlight a possible sequential pathway for performing QbD with the help of a case study. The main focus of this article is on the usage of failure mode and effect analysis (FMEA) as a tool for risk assessment, which helps in the identification of critical process parameters (CPPs) and critical material attributes (CMAs) and later on becomes the unbiased input for the design of experiments (DoE). In this case study, the DoE was helpful in establishing a risk-based relationship between critical quality attributes (CQAs) and CMAs/CPPs. Finally, a control strategy was established for all of the CPPs and CMAs, which in…

View original post 156 more words

Takeda’s ixazomib soon to be filed for multiple myeloma


Takeda's ixazomib soon to be filed for multiple myeloma

Takeda’s flagship experimental cancer drug ixazomib is a giant leap closer to being filed with regulatory authorities around the globe for multiple myeloma, after turning in a solid performance in late-stage trials.

Takeda’s ixazomib soon to be filed for multiple myeloma

 Read more at:

http://www.pharmatimes.com/Article/15-02-10/Takeda_s_ixazomib_soon_to_be_filed_for_multiple_myeloma.aspx

syn……….https://newdrugapprovals.org/2013/05/24/takeda-begins-phase-iii-trial-of-ixazomib-multiple-myeloma -drug/

Route Design in the 21st Century: The ICSYNTH Software Tool as an Idea Generator for Synthesis Prediction


Figure

 

The new computer-aided synthesis design tool ICSYNTH has been evaluated by comparing its performance in predicting new ideas for route design to that of historical brainstorm results on a series of commercial pharmaceutical targets, as well as literature data. Examples of its output as an idea generator are described, and the conclusion is that it adds appreciable value to the performance of the professional drug research and development chemist team.

Chemical Development, AstraZeneca R&D, Silk Road Business Park, Macclesfield, SK10 2NA Cheshire, U.K.
Chemnotia AB, Forskargatan 20 J, 151 36 Södertälje,Sweden
§ InfoChem GmbH, Landsberger Straße 408/V, D-81241 München, Germany
Org. Process Res. Dev., Article ASAP
DOI: 10.1021/op500373e
Publication Date (Web): January 22, 2015
Copyright © 2015 American Chemical Society
*(H.-J.F.) E-mail: Hans-Jurgen.Federsel@astrazeneca.com., *(M.G.H.) E-mail: mghutchings@infochem.de.
Currently, ICSYNTH has assumed a place as a unique predictive tool for route design in Chemical Development in AZ. While it is finding valuable commercial application in our own and others’ hands, it remains a work in progress.
ICsynthInfoChem’s powerful synthesis planning tool now in Version 2.0. Read more …

InfoChem will be represented at the forthcoming ACS Meeting in San Diego. You will find Dr. Josef Eiblmaier, Dr. Valentina Eigner Pitto, and Dr. Peter Loew …
ICSYNTH
InfoChem’s ICSYNTH is a powerful computer aided synthesis design tool that enables chemists to generate synthetic pathways for a target molecule. The benefit is that ICSYNTH can facilitate innovation by stimulating ideas for alternative or novel synthetic routes that otherwise may not be considered. This may lead to improved route design, for example shorter pathways or more economical reaction modifications.

After inputting the target, users can select different synthetic strategies depending on requirements. ICSYNTH then automatically generates a multistep interactive synthesis tree – each node on the tree representing a precursor. The advantages are that the suggested reactions are based on, and linked to, published reactions (or their analogs) and the precursor availability is automatically checked in commercial catalogs. Users can modify the synthesis tree or select precursors for further analysis.

At the heart of ICSYNTH is an algorithmic chemical knowledge base of transform libraries that are automatically generated from reaction databases. The number of transform libraries is only limited by the availability of validated reaction databases.
In addition to retro synthesis design, ICSYNTH has a forward reaction prediction module that offers reactivity mapping for the target molecule. Version 2.0 of ICSYNTH was launched in April 2014. The completely re-designed user interface (based on JavaScript) and major improvements in the algorithm responsible of the precursor search are the main enhancements of Version 2.0. In addition the forward reaction prediction algorithm has been optimized. Click here to see a complete version history.

INFOCHEM GESELLSCHAFT FÜR CHEMISCHE INFORMATION MBH

Landsberger Straße 408/V
D-81241 München
Germany

Phone: +49 (0)89 58 30 02
Fax: +49 (0)89 580 38 39
Email: info@infochem.de

 

Historische Bilder der Landsberger Straße – An der Trambahnhaltestelle Holzapfelstraße endet – Münchner Straßen – München – Süddeutsche.de

 

USP Chapter Visual Inspection of Injections published


DR ANTHONY MELVIN CRASTO Ph.D's avatarDRUG REGULATORY AFFAIRS INTERNATIONAL

The long-awaited USP Chapter <1790> regarding the 100% visual control of injections has been issued in the Pharmacopeial Forum 41(1) for commenting. Read on.

http://www.gmp-compliance.org/enews_4682_USP-Chapter–1790–Visual-Inspection-of-Injections-published_40007,9087,9200,Z-PEM_n.html

The long-awaited USP Chapter <1790> regarding the 100% visual control of injectables has now been issued as a first draft in the Pharmacopeial Forum 41(1) for commenting.

The new chapter is comprised of the following sub-chapters:
1. Scope
2. Introduction
3. Typical Inspection Process Flow
4. Inspection Life-Cycle
5. Interpretation of Results
6. Inspection Methods and Technologies
7. Qualification and Validation of Inspection Processes
8. Conclusions and Recommendations
9. References

This new informative chapter is applied to the manual, the half-automatic and the fully-automated inspection of parenterals. It mainly aims at controlling particles (>50 µm), but also comprises indications to further defects like cracks in primary containers or poorly fitting stoppers. In Chapter 2 there are also general statements regarding the patient risk due to…

View original post 329 more words

FDA approves Pfizer’s Ibrance (palbociclib) for postmenopausal women with advanced breast cancer


PALBOCICLIB

Mechanism of action: selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
Indication: Estrogen receptor-positive (ER+), HER2-negative (HER2 -) breast cancer

FDA approves Ibrance for postmenopausal women with advanced breast cancer

February 3, 2015

syn……….https://newdrugapprovals.org/2014/01/05/palbociclib/

The U.S. Food and Drug Administration today granted accelerated approval to Ibrance (palbociclib) to treat advanced (metastatic) breast cancer.

Breast cancer in women is the second most common type of cancer in the United States. It forms in the breast tissue and in advanced cases, spreads to surrounding normal tissue. The National Cancer Institute estimates that 232,670 American women were diagnosed with breast cancer and 40,000 died from the disease in 2014.

Ibrance works by inhibiting molecules, known as cyclin-dependent kinases (CDKs) 4 and 6, involved in promoting the growth of cancer cells. Ibrance is intended for postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have not yet received an endocrine-based therapy. It is to be used in combination with letrozole, another FDA-approved product used to treat certain kinds of breast cancer in postmenopausal women.

“The addition of palbociclib to letrozole provides a novel treatment option to women diagnosed with metastatic breast cancer,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “The FDA is committed to expediting marketing approval of cancer drugs through our accelerated approval regulations.”

syn……….https://newdrugapprovals.org/2014/01/05/palbociclib/

The FDA granted Ibrance breakthrough therapy designation because the sponsor demonstrated through preliminary clinical evidence that the drug may offer a substantial improvement over available therapies. It also received a priority review, which provides for an expedited review of drugs intended to provide a significant improvement in safety or effectiveness in the treatment of a serious condition or meet an unmet medical need. Ibrance is being approved more than two months ahead of the prescription drug user fee goal date of April 13, 2015, the date when the agency was scheduled to complete its review of the application.

Ibrance is being approved under the FDA’s accelerated approval program, which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients. This program provides earlier patient access to promising new drugs while the company conducts confirmatory clinical trials.

The drug’s efficacy was demonstrated in 165 postmenopausal women with ER-positive, HER2-negative advanced breast cancer who had not received previous treatment for advanced disease. Clinical study participants were randomly assigned to receive Ibrance in combination with letrozole or letrozole alone. Participants treated with Ibrance plus letrozole lived about 20.2 months without their disease progressing (progression-free survival), compared to about 10.2 months seen in participants receiving only letrozole. Information on overall survival is not available at this time.

The most common side effects of the drug were a decrease in infection-fighting white blood cells called neutrophils (neutropenia), low levels of white blood cells (leukopenia), fatigue, low red blood cell counts (anemia), upper respiratory infection, nausea, inflammation of the lining of the mouth (stomatitis), hair loss (alopecia), diarrhea, low blood platelet counts (thrombocytopenia), decreased appetite, vomiting, lack of energy and strength (asthenia), damage to the peripheral nerves (peripheral neuropathy) and nosebleed (epistaxis). Healthcare professionals should inform patients of these risks.

It is recommended that treatment begin with a 125 milligram dose for 21 days, followed by seven days without treatment. Healthcare professionals are advised to monitor complete blood count prior to start of therapy and at the beginning of each cycle, as well as on Day 14 of the first two cycles, and as clinically indicated.

Ibrance is marketed by New York City-based Pfizer, Inc.

see synthesis……….https://newdrugapprovals.org/2014/01/05/palbociclib/

 

New York City-based Pfizer, Inc.

 

Pfizer World Headquarters building in New York City. Zoetis, based in Madison, N.J., traces its roots back to 1952 as a Pfizer unit and has made at least 10 …

Pfizer’s NYC headquarters

 

Falsified Results of Analysis at Indian Pharmaceutical Manufacturer


DR ANTHONY MELVIN CRASTO Ph.D's avatarDRUG REGULATORY AFFAIRS INTERNATIONAL

Indian pharmaceutical manufacturers increasingly attract attention by breaching GMP rules. In a further case the analysis results not complying with the requirements were deleted and the batch was released for the US market. Read more.

http://www.gmp-compliance.org/enews_4629_Falsified-Results-of-Analysis-at-Indian-Pharmaceutical-Manufacturer_9086,9087,9200,9122,Z-PEM_n.html

Indian pharmaceutical manufacturers increasingly attract attention by breaching GMP rules. We recently reported on theunannounced FDA inspections in India as one of the consequences of this practice. In a further case the analysis results not complying with the requirements were deleted and the batch was released for the US market. An employee of Sun Pharmaceutical Industries Ltd. in Vadodara, India simply deleted analytical data of an HPLC testing on impurities of an antibiotic that did not comply. The next day another sample was tested, considered to be fine and the batch was released. This incident took place three years ago.

This fundamental GMP violation of data integrity has become known only now. The…

View original post 266 more words

EDIVOXETINE REVISITED


Edivoxetine structure.png

EDIVOXETINE, LY 2216684

(1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(oxan-4-yl)ethanol

UNII-3W9N3F4JOO, 1194508-25-2, Edivoxetine [USAN], Edivoxetine (USAN/INN), Edivoxetine [USAN:INN], 3W9N3F4JOO
Molecular Formula:C18H26FNO4
Molecular Weight:339.401743 g/mol

Edivoxetine (INN; LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant treatment.[1][2] It was in phase IIIclinical trials, in 2012, for major depressive disorder, but failed to get approval.[1][3]

 

Effectiveness

In a study published in 2010, edivoxetine failed to prove superiority over placebo, as measured by Hamilton Depression Rating Scale. However, effectiveness could be observed using the Self-Rated Quick Inventory of Depressive Symptomatology.[4]

In a study published in 2011, using the Montgomery-Åsberg Depression Rating Scale and the Sheehan Disability Scale, edivoxetine showed superiority over placebo, with higher response and remission rates.[5]

In December 2013, Eli Lilly announced that the clinical development of edivoxetine will be stopped due to lack of efficacy compared to SSRI alone in three separate clinical trials.[6]

Side effects

Side effects significantly associated with edivoxetine are headache, nausea, constipation, dry mouth and insomnia.[4]

The above mention studies report increases of the cardiac rhythm, and one also increases of diastolic and systolic blood pressures.[4][5]

Figure

Org. Process Res. Dev., Article ASAP
DOI: 10.1021/op5003825

There is a growing trend in Ireland toward greater collaboration between academia and the pharmaceutical industry. This is an activity encouraged at a national policy level as a means of providing researchers from academic institutions the opportunity to gain important first-hand experience in a commercial research environment, while also providing industry access to expertise and resources to develop new and improved processes for timely medicines. The participating company benefits in terms of its growth, the evolution of its strategic research and development, and the creation of new knowledge that it can use to generate commercial advantage. The research institute benefits in terms of developing skill sets, intellectual property, and publications, in addition to access to identified current industry challenges. A case study is provided describing the collaborative partnership between a synthetic chemistry research team at University College Cork (UCC) and Eli Lilly and Company.

Department of Chemistry and School of Pharmacy, Analytical and Biological Chemistry Research Facility, Synthesis and Solid State Pharmaceutical Centre,University College Cork, Cork, Ireland

University College Cork

Systematic (IUPAC) name
(1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(tetrahydro-2H-pyran-4-yl)ethanol
Clinical data
Legal status
?
Identifiers
CAS number 1194508-25-2
1194374-05-4 (hydrochloride)
ATC code None
PubChem CID 11186829
ChemSpider 9361913
Chemical data
Formula C18H26FNO4 
Molecular mass 339.402 g/mol

References

  1.  Jun Yan (March 2012). “Pipeline for new antidepressants flowing slowly”. Psychiatric News (American Psychiatric Association) 47 (5): 1b-29. Retrieved 2012-04-27.
  2.  “Statement on a nonproprietary name adopted by the USAN council – Edivoxetine” (Press release). American Medical Association. 2012. Retrieved 2012-04-12.
  3.  Chancellor D (November 2011). “The depression market”. Nature Reviews. Drug Discovery 10 (11): 809–10. doi:10.1038/nrd3585. PMID 22037032.
  4.  Dubé S, Dellva MA, Jones M, Kielbasa W, Padich R, Saha A, Rao P (April 2010). “A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression”. Journal of Psychiatric Research 44 (6): 356–363. doi:10.1016/j.jpsychires.2009.09.013. PMID 19909980.
  5.  Pangallo P, Dellva MA, D’Souza DN, Essink B, Russell J, Goldberger C (June 2011). “A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder”. Journal of Psychiatric Research 45 (6): 748–755. doi:10.1016/j.jpsychires.2011.03.014. PMID 21511276.
  6.  https://investor.lilly.com/releasedetail.cfm?ReleaseID=811751
H-NMR spectral analysis
(1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(oxan-4-yl)ethanol NMR spectra analysis, Chemical CAS NO. 1194508-25-2 NMR spectral analysis, (1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(oxan-4-yl)ethanol H-NMR spectrum
CAS NO. 1194508-25-2, (1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(oxan-4-yl)ethanol H-NMR spectral analysis
C-NMR spectral analysis
(1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(oxan-4-yl)ethanol NMR spectra analysis, Chemical CAS NO. 1194508-25-2 NMR spectral analysis, (1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(oxan-4-yl)ethanol C-NMR spectrum
CAS NO. 1194508-25-2, (1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(oxan-4-yl)ethanol C-NMR spectral analysis

/////////////

MAHABALIPURAM, INDIA

Mahabalipuram – Wikipedia, the free encyclopedia

en.wikipedia.org/wiki/Mahabalipuram

Mahabalipuram, also known as Mamallapuram is a town in Kancheepuram district in the Indian state of Tamil Nadu. It is around 60 km south from the city of …Shore Temple – ‎Seven Pagodas – ‎Pancha Rathas – ‎

Map of mahabalipuram.

.

Krishna’s Butter Ball in Mahabalipuram, India. The surface below the rock is …


http://www.weather-forecast.com/locations/Mamallapuram


Come to Mahabalipuram (also known as Mammallapuram), an enchanting beach that is located on the east coast of India.
Moonraikers Restaurant, Mamallapuram
 

Hotel Mamalla Bhavan – Mahabalipuram Chennai – Food, drink and entertainment

.

A carving at the Varaha Temple, Mahabalipuram

/////////////

(sNDA)…..FDA okays Shire ADHD drug Vyvanse (lisdexamfetamine dimesylate) for binge eating


 

 

Lisdexamfetamine-Structural Formula V.1.svg

Yet more good news for Shire has come with the US Food and Drug Administration approving its attention-deficit hyperactivity disorder blockbuster Vyvanse for binge-eating disorder, the first medicine approved by the agency to treat this condition.

The agency has expanded approval on Vyvanse (lisdexamfetamine dimesylate) for adults with BED based on two Phase III studies which showed that it was statistically superior to placebo in terms of number of binge days per week. BED affects around 2.8 million US adults and is more prevalent than anorexia nervosa and bulimia nervosa combined.

Read more at: http://www.pharmatimes.com/Article/15-01-30/FDA_okays_Shire_ADHD_drug_Vyvanse_for_binge_eating.aspx

 

Originally discovered and developed by New River Pharmaceuticals, the company entered into a collaborative agreement with Shire Pharmaceuticals in 2005 for global commercialization of the drug candidate. After Shire’s acquisition of New River Pharmaceuticals in April 2007, lisdexamfetamine entered the product portfolio of Shire.

 

 

 

In 2009, the compound was licensed to GlaxoSmithKline by Shire in the U.S. for comarketing for the treatment of attention deficit/hyperactivity disorder (ADHD). In 2010, this license agreement was terminated. The product was licensed to Shionogi by Shire in Japan for co-development, co-commercialization, and co-promotion for the treatment of attention deficit/hyperactivity disorder (ADHD).

Lisdexamfetamine (NRP-104), a conditionally bioreversible derivative of amphetamine, was launched in the U.S. in 2007 for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6-12 years old. In 2008, the product was approved for use in adults, and in 2009 it was approved in Canada, followed by commercialization in 2010. In 2010, FDA approval was obtained for use in treatment of ADHD in adolescents aged 13 to 17 years and launch took place the same year. Approval for the treatment of adolescents was assigned in Canada in 2011.

 

In 2012, Shire filed a regulatory application in Europe via the decentralized procedure with the U.K. acting as the reference member state, for the treatment of ADHD in children and adolescent patients aged 6 to 17 years. This indication was approved in 2013. Also, in 2012 FDA approval was granted for the maintenance treatment for adults with ADHD. U.K., DK and SE are awaiting approval for the same indication in a decentralized procedure initiated in 2014 with the U.K. acting as the reference member state. In 2014, the company filed with priority review a supplemental New Drug Application (sNDA) in the U.S. for the treatment binge eating in adults.
cas 608137-33-3

(2S)-2,6-Diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimethanesulfonate

Binge eating,,,,,, express their stress as temper tantrums or by indulging in compulsive eating spree


In terms of clinical development, phase III clinical trials are ongoing at Shionogi in Japan for the treatment of ADHD.. The National Institute on Drug Abuse (NIDA) is evaluating the compound in early clinical studies for the treatment of methamphetamine dependence. Phase III trials were underway as an adjunctive treatment of major depressive disorder; however, they were discontinued due to lack of efficacy. A phase II clinical trial for the treatment of excessive daytime sleepiness (EDS) has been completed. Shire had been evaluating the compound in clinical studies for the treatment of chronic fatigue syndrome.

In 2013, Shire cancelled its phase III program evaluating the product for the negative symptoms of schizophrenia based on a review and prioritization of the company’s development portfolio.

http://www.google.co.in/patents/US7662787

RIVER PHARMA

NEW RIVER PHARMACEUTICALS

 

Patent and Exclusivity Search Results from query on Appl No 021977 Product 003 in the OB_Rx list.


Patent Data

Appl No Prod No Patent No Patent
Expiration
Drug Substance
Claim
Drug Product
Claim
Patent Use
Code
Delist
Requested
N021977 003 7105486 Jun 29, 2023 U – 727
N021977 003 7223735 Jun 29, 2023 Y
N021977 003 7655630 Feb 24, 2023 Y
N021977 003 7659253 Feb 24, 2023 Y Y U – 727
N021977 003 7659254 Feb 24, 2023 U – 1034
N021977 003 7662787 Feb 24, 2023 Y
N021977 003 7662788 Feb 24, 2023 U – 727
N021977 003 7671030 Feb 24, 2023 Y U – 727
N021977 003 7671031 Feb 28, 2023 U – 727
N021977 003 7674774 Mar 18, 2023 Y U – 842
N021977 003 7678770 Mar 25, 2023 U – 842
N021977 003 7678771 Mar 25, 2023 Y U – 842
N021977 003 7687466 Feb 24, 2023 Y
N021977 003 7687467 Apr 8, 2023 Y U – 842
N021977 003 7700561 Jun 29, 2023 Y
N021977 003 7713936 Feb 24, 2023 U – 727
N021977 003 7718619 Feb 24, 2023 Y U – 842
N021977 003 7723305 Feb 24, 2023 Y U – 842

Exclusivity Data

Appl No Prod No Exclusivity Code Exclusivity Expiration
N021977 003 I – 645 Jan 31, 2015

Lead-oriented synthesis: a new concept to aid drug-discovery process


 

Figure 2. a. Fragment-based screening: Small and structurally diverse molecules (circles represent functional groups) are screened for a biological target, and they are combined and modified to generate drug-like compounds. b. Diversity-oriented synthesis: Large collections of structurally diverse and complex molecules are made using a short number of reactions. The resulting compounds are optimized to produce the drug-like compounds. | Credit: P. J. Hajduk,W. R. J. D. Galloway & D. R. Spring Nature, 2011, 470, 42–43. DOI: 10.1038/470042a

 

The discovery and development of new drugs is a long and expensive process, and despite of it, essential to face present and new diseases. For small molecules, which account for the majority of the marketed drugs, the discovery process generally involves finding a starting point termed hit or lead compound. These molecules have biological activity but need to be optimized to enhance their potency and selectivity (i.e. minimize the toxicity) and improve pharmacokinetic parameters making them suitable to go to the next stage, the pre-clinical tests……….http://mappingignorance.org/2014/07/04/lead-oriented-synthesis-new-concept-aid-drug-discovery-process/

 

Author

pablo ortiz

Pablo Ortiz
Pablo Ortiz graduated in Pharmacy from the University of the Basque Country (UPV/EHU) and received a MSc in Synthetic and Industrial Chemistry by the same university. He is currently a PhD student in Synthetic Organic Chemistry at the University of Groningen (The Netherlands). His research is focused on novel copper catalysed transformations.

PhD at Rijksuniversiteit Groningen

Experience

PhD StudentRijksuniversiteit Groningen

October 2013 – Present 

Asymmetric organometallic catalysis focused on tertiary alcohols and amines

Harutyunyan research group

Harutyunyan research group

Master Thesis Project

University of the Basque Country

February 2013 – September 2013 (8 months)Vitoria-Gasteiz Area, Spain

Estereoselective synthesis of quaternary alpha-aminophosphonic acid derivatives (organocatalysis)

Locum pharmacist

Community pharmacy

August 2012 – August 2012 (1 month)La Rioja, Spain

Pre-registration pharmacist

NHS Trust

January 2012 – June 2012 (6 months)Southport, England

In-patient and out-patient dispensing
Clinical pharmacy
Medicines information
Anticoagulant management
Aseptic preparation of medicines
Clinical audit of antimicrobial use

Publications

Tertiary α-diarylmethylamines derived from diarylketimines and organomagnesium reagents(Link)

Chem. Commun. 2015, 51, 703-706.

November 13, 2014

Organomagnesium reagents enable swift and versatile derivatisation of diarylimines to the corresponding α-substituted diarylmethylamines in excellent yields, through fast and clean reactions. Where it occurs, 1,2-reduction can be circumvented using readily accessible dialkylmagnesium reagents.

Asymmetric Synthesis of Functionalized Tetrasubstituted α-Aminophosphonates through Enantioselective Aza-Henry Reaction of Phosphorylated Ketimines(Link)

J. Org. Chem., 2015, 80, 156–164

November 2014

Bifunctional Cinchona alkaloid thioureas efficiently catalyze asymmetric nucleophilic addition of nitromethane to ketimines derived from α-aminophosphonic acids to afford tetrasubstituted α-amino-β-nitro-phosphonates.

Catalytic Asymmetric Alkylation of Aryl Heteroaryl Ketones(Link)

Eur. J. Org. Chem., 2015, 72–76.

November 2014

Tertiary diarylmethanols are highly bioactive structural motifs. A new strategy to access chiral tertiary diarylmethanols through copper-catalyzed direct alkylation of (di)(hetero)aryl ketones by using Grignard reagents was developed. The low reactivity and the similarity of the enantiotopic faces of bis-aromatic ketones were partially overcome, which resulted in moderate to good yields and…more

Education

Universidad del País Vasco/Euskal Herriko Unibertsitatea

Bachelor’s degree, Pharmacy, Extraordinary Degree Award, 9.06

2007 – 2012

(Open)1 honor or award
(Open)2 courses

Courses

Universidad del País Vasco/Euskal Herriko Unibertsitatea

  • How to write and publish a research article
  • X Pharmaceutical Chemistry Sessions: New strategies for the design and synthesis of drugs

Universidad del País Vasco/Euskal Herriko Unibertsitatea

  • II Organic Chemistry Synthesis and Catalysis Workshop: Methods and strategies in synthesis

 

GRONINGEN, NETHERLANDS

 

Map of groningen the netherlands

http://www.rug.nl/

Groningen City – Holland.

stadtmitte groningen niederlande stadtwanderung

Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

DISCLAIMER

I , Dr A.M.Crasto is writing this blog to share the knowledge/views, after reading Scientific Journals/Articles/News Articles/Wikipedia. My views/comments are based on the results /conclusions by the authors(researchers). I do mention either the link or reference of the article(s) in my blog and hope those interested can read for details. I am briefly summarising the remarks or conclusions of the authors (researchers). If one believe that their intellectual property right /copyright is infringed by any content on this blog, please contact or leave message at below email address amcrasto@gmail.com. It will be removed ASAP